These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 20962860

  • 1. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.
    Carney DA, Westerman DA, Tam CS, Milner A, Prince HM, Kenealy M, Wolf M, Januszewicz EH, Ritchie D, Came N, Seymour JF.
    Leukemia; 2010 Dec; 24(12):2056-62. PubMed ID: 20962860
    [Abstract] [Full Text] [Related]

  • 2. Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation.
    Waterman J, Rybicki L, Bolwell B, Copelan E, Pohlman B, Sweetenham J, Dean R, Sobecks R, Andresen S, Kalaycio M.
    Bone Marrow Transplant; 2012 Apr; 47(4):488-93. PubMed ID: 21572461
    [Abstract] [Full Text] [Related]

  • 3. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.
    Colović M, Suvajdžić N, Janković G, Tomin D, Colović N, Fekete MD, Palibrk V.
    Biomed Pharmacother; 2011 Aug; 65(5):319-21. PubMed ID: 21775097
    [Abstract] [Full Text] [Related]

  • 4. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
    Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, Hines JD, Shepherd L, Larson RA, Schiffer CA.
    J Clin Oncol; 2002 Sep 15; 20(18):3878-84. PubMed ID: 12228208
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series.
    Pedersen-Bjergaard J, Philip P, Larsen SO, Andersson M, Daugaard G, Ersbøll J, Hansen SW, Hou-Jensen K, Nielsen D, Sigsgaard TC.
    Leukemia; 1993 Dec 15; 7(12):1975-86. PubMed ID: 8255096
    [Abstract] [Full Text] [Related]

  • 8. Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone.
    Au WY, Chan LC, Liang R, Kwong YL.
    Am J Hematol; 2006 Jun 15; 81(6):471-3. PubMed ID: 16680740
    [No Abstract] [Full Text] [Related]

  • 9. Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience.
    Aguilera DG, Vaklavas C, Tsimberidou AM, Wen S, Medeiros LJ, Corey SJ.
    J Pediatr Hematol Oncol; 2009 Nov 15; 31(11):803-11. PubMed ID: 19801947
    [Abstract] [Full Text] [Related]

  • 10. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J.
    J Clin Oncol; 2008 Feb 01; 26(4):577-84. PubMed ID: 18086801
    [Abstract] [Full Text] [Related]

  • 11. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
    Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J, Engert A, Diehl V, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2003 Sep 15; 21(18):3440-6. PubMed ID: 12668650
    [Abstract] [Full Text] [Related]

  • 12. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR, German Cooperative Transplant Study Group.
    Ann Hematol; 2003 Jun 15; 82(6):336-42. PubMed ID: 12728337
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
    Nevill TJ, Hogge DE, Toze CL, Nantel SH, Power MM, Abou Mourad YR, Song KW, Lavoie JC, Forrest DL, Barnett MJ, Shepherd JD, Nitta JY, Wong S, Sutherland HJ, Smith CA.
    Bone Marrow Transplant; 2008 Nov 15; 42(10):659-66. PubMed ID: 18679372
    [Abstract] [Full Text] [Related]

  • 15. Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia.
    Lam CC, Ma ES, Kwong YL.
    Am J Hematol; 2005 Aug 15; 79(4):288-90. PubMed ID: 16044456
    [Abstract] [Full Text] [Related]

  • 16. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN, Gregory W, Hudson GV, Devereux S, Goldstone AH, Hancock B, Winfield D, MacMillan AK, Hoskin P, Newland AC, Milligan D, Linch DC.
    Br J Cancer; 1999 Oct 15; 81(3):476-83. PubMed ID: 10507773
    [Abstract] [Full Text] [Related]

  • 17. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
    Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Andresen S, Kuczkowski E, Bolwell B.
    J Clin Oncol; 2006 Aug 01; 24(22):3604-10. PubMed ID: 16877727
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia.
    Batzios C, Hayes LA, He SZ, Quach H, McQuilten ZK, Wall M, Campbell LJ.
    Am J Hematol; 2009 Nov 01; 84(11):715-9. PubMed ID: 19806661
    [Abstract] [Full Text] [Related]

  • 20. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
    Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R, Ciccarelli BT, Sacco A, Ioakimidis L, Adamia S, Moreau AS, Patterson CJ, Ghobrial IM, Treon SP.
    J Clin Oncol; 2009 Jan 10; 27(2):250-5. PubMed ID: 19064987
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.